DemeRx Receives FDA Clearance for Novel Neuroplastogen DMX-1001 to Treat Alcohol Use Disorder
Key Insights
The FDA has accepted DemeRx (search)'s IND application for DMX-1001 (search), a novel oral noribogaine neuroplastogen therapeutic targeting alcohol use disorder (search).
DMX-1001 (search) combines neuroplasticity and polypharmacology mechanisms, offering potential disease-modifying treatment for the 29 million Americans affected by AUD (search).
The company completed a successful multiple ascending dose trial in healthy volunteers, demonstrating safety and tolerability profiles supporting Phase 2 advancement.
DemeRx (search), Inc. has received FDA acceptance of its Investigational New Drug (IND) application for DMX-1001 (search) (oral noribogaine), marking a significant regulatory milestone for the novel neuroplastogen therapeutic designed to treat alcohol use disorder (search) (AUD (search)). The "safe to proceed" authorization enables the clinical-stage biopharmaceutical company to advance toward Phase 2 clinical trials targeting a condition that affects more than 29 million Americans.
Novel Mechanism Targets Neuroplasticity
DMX-1001 (search) represents a distinctive therapeutic approach that combines neuroplasticity and polypharmacology mechanisms of action. The drug is based on noribogaine, a long-acting metabolite of ibogaine that remains in the body for extended periods compared to its parent compound. This prolonged presence drives long-term neuroplastic changes aimed at repairing neural circuits damaged by chronic substance abuse.
"DMX-1001 (search) is a 'pipeline in a drug' that has rapid antidepressant and anti-anxiety (search) effects," according to the company. This dual action addresses a critical aspect of AUD (search) treatment, as alcohol use disorder (search) is often associated with mental health disorders, including depression (search) and anxiety, which increase relapse risk for individuals in early recovery.
Successful Preclinical Foundation
The FDA acceptance follows DemeRx (search)'s recent completion of a multiple ascending dose (MAD) clinical trial of DMX-1001 (search) in healthy volunteers. Results from the MAD study demonstrated safety, tolerability, and pharmacokinetics profiles that support advancing the compound to Phase 2 clinical trials in people with AUD (search).
"We are grateful to the FDA for their timely review of our IND application for DMX-1001 (search) for the treatment of AUD (search)," said Deborah Mash, Ph.D., CEO and founder of DemeRx (search). "The 'safe to proceed' authorization marks an important milestone both for patients with AUD and the growth of our company."
Addressing Critical Unmet Medical Need
The regulatory advancement comes amid stark statistics highlighting the urgent need for effective AUD (search) treatments. Alcohol use disorder (search) affects more than 29 million people in the United States and represents a leading cause of preventable death. Current treatment outcomes reveal significant gaps in care: fewer than five percent of those suffering from AUD receive medication, and approximately 60 percent of treated patients relapse to hazardous drinking within six months.
"There is tremendous need for innovative, disease-modifying approaches to treat alcohol and other substance use disorders (search) and we're excited about the potential of DMX-1001 (search) to address this serious unmet need," Mash stated.
Clinical Development Timeline
DemeRx (search) anticipates initiating the Phase 2 clinical trial of DMX-1001 (search) in AUD (search) patients in 2027. The company plans to complete an alcohol interaction trial as part of its development program, with successful completion supporting the Phase 2 clinical start timeline.
The neuroplastogen approach represents a potentially transformative strategy for addiction therapeutics, focusing on repairing underlying neural damage rather than solely managing symptoms. This disease-modifying potential could address the high relapse rates that characterize current AUD (search) treatment outcomes.